LDE225
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma
Trial Timeline
Feb 1, 2012 → Aug 1, 2013
NCT ID
NCT01529450About LDE225
LDE225 is a pre-clinical stage product being developed by Novartis for Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01529450. Target conditions include Basal Cell Carcinoma.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02195973 | Phase 1 | Completed |
| NCT02151864 | Phase 1 | Completed |
| NCT02086513 | Phase 1 | Terminated |
| NCT02002689 | Phase 2 | Terminated |
| NCT01826214 | Phase 2 | Completed |
| NCT01764776 | Phase 1 | Completed |
| NCT01529450 | Pre-clinical | Completed |
| NCT01327053 | Phase 2 | Completed |
| NCT01125800 | Phase 1/2 | Completed |
| NCT01208831 | Phase 1 | Completed |
| NCT00880308 | Phase 1 | Completed |
Competing Products
20 competing products in Basal Cell Carcinoma